PL377735A1 - Pochodne kwasu 4-(3-(2-fenylooksazol-4-ilometoksy)- cykloheksyloksy)- propano-1-karboksylowego i związki pokrewne, jako modulatory PPAR do leczenia cukrzycy typu 2 i stwardnienia naczyń - Google Patents

Pochodne kwasu 4-(3-(2-fenylooksazol-4-ilometoksy)- cykloheksyloksy)- propano-1-karboksylowego i związki pokrewne, jako modulatory PPAR do leczenia cukrzycy typu 2 i stwardnienia naczyń

Info

Publication number
PL377735A1
PL377735A1 PL377735A PL37773504A PL377735A1 PL 377735 A1 PL377735 A1 PL 377735A1 PL 377735 A PL377735 A PL 377735A PL 37773504 A PL37773504 A PL 37773504A PL 377735 A1 PL377735 A1 PL 377735A1
Authority
PL
Poland
Prior art keywords
ylmethoxy
oxazol
cyclohexyloxy
atherosclerosis
phenyl
Prior art date
Application number
PL377735A
Other languages
English (en)
Polish (pl)
Inventor
Christian Stapper
Heiner Glombik
Eugen Falk
Jochen Goerlitzer
Dirk Gretzke
Stefanie Keil
Hans-Ludwig Schaefer
Wolfgang Wendler
Original Assignee
Sanofi-Aventis Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis Deutschland Gmbh filed Critical Sanofi-Aventis Deutschland Gmbh
Publication of PL377735A1 publication Critical patent/PL377735A1/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
PL377735A 2003-02-27 2004-02-19 Pochodne kwasu 4-(3-(2-fenylooksazol-4-ilometoksy)- cykloheksyloksy)- propano-1-karboksylowego i związki pokrewne, jako modulatory PPAR do leczenia cukrzycy typu 2 i stwardnienia naczyń PL377735A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10308355A DE10308355A1 (de) 2003-02-27 2003-02-27 Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
PL377735A1 true PL377735A1 (pl) 2006-02-20

Family

ID=32920629

Family Applications (3)

Application Number Title Priority Date Filing Date
PL378130A PL378130A1 (pl) 2003-02-27 2004-02-19 Pochodne kwasu 3-(2-fenylooksazol-4-ilometoksy)-cykloheksylometoksyoctowego i związki pokrewne, jako modulatory PPAR do leczenia cukrzycy typu 2 i stwardnienia naczyń
PL377735A PL377735A1 (pl) 2003-02-27 2004-02-19 Pochodne kwasu 4-(3-(2-fenylooksazol-4-ilometoksy)- cykloheksyloksy)- propano-1-karboksylowego i związki pokrewne, jako modulatory PPAR do leczenia cukrzycy typu 2 i stwardnienia naczyń
PL378437A PL378437A1 (pl) 2003-02-27 2004-02-19 Pochodne kwasu 3-metylo-2-(3-(2-fenylooksazol-4-ilometoksy)-cykloheksanokarbonyloamino)-masłowego i związki pokrewne, jako modulatory PPAR do leczenia cukrzycy typu 2 i stwardnienia naczyń

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL378130A PL378130A1 (pl) 2003-02-27 2004-02-19 Pochodne kwasu 3-(2-fenylooksazol-4-ilometoksy)-cykloheksylometoksyoctowego i związki pokrewne, jako modulatory PPAR do leczenia cukrzycy typu 2 i stwardnienia naczyń

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL378437A PL378437A1 (pl) 2003-02-27 2004-02-19 Pochodne kwasu 3-metylo-2-(3-(2-fenylooksazol-4-ilometoksy)-cykloheksanokarbonyloamino)-masłowego i związki pokrewne, jako modulatory PPAR do leczenia cukrzycy typu 2 i stwardnienia naczyń

Country Status (34)

Country Link
US (5) US7365084B2 (US07259177-20070821-C00075.png)
EP (3) EP1599453B1 (US07259177-20070821-C00075.png)
JP (3) JP2006519193A (US07259177-20070821-C00075.png)
KR (3) KR20050106462A (US07259177-20070821-C00075.png)
CN (3) CN100439347C (US07259177-20070821-C00075.png)
AR (3) AR043427A1 (US07259177-20070821-C00075.png)
AT (3) ATE435217T1 (US07259177-20070821-C00075.png)
AU (3) AU2004215673B2 (US07259177-20070821-C00075.png)
BR (3) BRPI0407907A (US07259177-20070821-C00075.png)
CA (3) CA2517386A1 (US07259177-20070821-C00075.png)
CL (2) CL2004000391A1 (US07259177-20070821-C00075.png)
CO (2) CO5690580A2 (US07259177-20070821-C00075.png)
DE (4) DE10308355A1 (US07259177-20070821-C00075.png)
DK (3) DK1599453T3 (US07259177-20070821-C00075.png)
EC (2) ECSP055986A (US07259177-20070821-C00075.png)
ES (3) ES2287700T3 (US07259177-20070821-C00075.png)
HR (3) HRP20050744A2 (US07259177-20070821-C00075.png)
IL (2) IL170314A (US07259177-20070821-C00075.png)
MA (3) MA27742A1 (US07259177-20070821-C00075.png)
MX (3) MXPA05008951A (US07259177-20070821-C00075.png)
NO (3) NO20054398L (US07259177-20070821-C00075.png)
OA (2) OA13035A (US07259177-20070821-C00075.png)
PA (1) PA8596801A1 (US07259177-20070821-C00075.png)
PE (3) PE20040959A1 (US07259177-20070821-C00075.png)
PL (3) PL378130A1 (US07259177-20070821-C00075.png)
PT (3) PT1599452E (US07259177-20070821-C00075.png)
RS (1) RS20050594A (US07259177-20070821-C00075.png)
RU (3) RU2005129995A (US07259177-20070821-C00075.png)
SA (1) SA04250153A (US07259177-20070821-C00075.png)
TN (2) TNSN05204A1 (US07259177-20070821-C00075.png)
TW (3) TW200510352A (US07259177-20070821-C00075.png)
UY (2) UY28209A1 (US07259177-20070821-C00075.png)
WO (3) WO2004076426A1 (US07259177-20070821-C00075.png)
ZA (2) ZA200505768B (US07259177-20070821-C00075.png)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576131B2 (en) 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7399777B2 (en) * 2001-08-31 2008-07-15 Sanofi-Aventis Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
DE10308353A1 (de) * 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004038403B4 (de) * 2004-08-07 2006-08-31 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten
DE102004039509B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004039533B4 (de) 2004-08-14 2006-09-28 Sanofi-Aventis Deutschland Gmbh Essigsäurederivate mit Cyclohexylmethoxy-Substituenten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039532B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Cyclohexyl-methyloxy substituierte Essigsäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004060227B3 (de) 2004-12-15 2006-07-20 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Oxazolen durch Kondensation von aromatischen Aldehyden mit α-Ketoximen zu N-Oxiden und nachfolgende Reaktion mit aktivierten Säurederivaten
GT200600218A (es) * 2005-06-10 2007-03-28 Formulación y proceso de compresión directa
WO2007039177A2 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
KR101398715B1 (ko) 2006-08-10 2014-05-27 가부시키가이샤 미모잭스 아카시아속 나무 껍질 유래물을 함유하는 혈당 강하 조성물
EP2181087B1 (en) 2007-08-16 2015-10-14 Solvay Sa Process for the preparation of esters of 4-fluorosubstituted 3-oxo-alcanoic acids
CN103435593B (zh) * 2008-02-29 2015-01-28 日产化学工业株式会社 噻吩化合物及其中间体的制造方法
US7615661B2 (en) * 2008-03-12 2009-11-10 International Flavors & Fragrances Inc. Thioester compounds and their use in fragrance or flavor applications
MA51156A (fr) 2017-12-13 2020-10-21 Canon Kk Cartouche et dispositif de formation d'image
CN109810071B (zh) * 2019-03-28 2023-04-21 中国科学院成都生物研究所 一种miRNA生物合成抑制剂

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2663464B1 (fr) * 1990-06-19 1992-09-11 Commissariat Energie Atomique Circuit integre en technologie silicium sur isolant comportant un transistor a effet de champ et son procede de fabrication.
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
ZA941003B (en) 1993-02-15 1995-08-14 Wellcome Found Hypolipidaemic compounds
JP3144624B2 (ja) 1995-06-02 2001-03-12 杏林製薬株式会社 N−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
KR19990077319A (ko) 1996-01-17 1999-10-25 한센 핀 베네드, 안네 제헤르 축합된 1,2,4-티아디아진 및 축합된 1,4-티아진 유도체, 그것의제조방법 및 사용
DE69737479T4 (de) 1996-08-30 2010-05-06 Novo Nordisk A/S Glp-1 derivate
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
JP4339402B2 (ja) 1996-12-31 2009-10-07 ドクター・レディーズ・ラボラトリーズ・リミテッド 新規なヘテロ環化合物、これらの製造方法及びこれらを含有する薬学的組成物、並びに糖尿病及び関連疾患の治療におけるこれらの使用
DE19726167B4 (de) * 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
BR9810592A (pt) 1997-07-16 2000-09-12 Novo Nordisk As Composto, processos para preparar um composto, para tratar ou prevenir doenças do sistema endócrino e para a fabricação de um medicamento, composição farmacêutica, e, uso de um composto
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
EP1067109B1 (en) * 1998-03-10 2009-12-09 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
MA26634A1 (fr) 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
SE9801992D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
WO2000012491A1 (fr) * 1998-08-27 2000-03-09 Ono Pharmaceutical Co., Ltd. Derives d'acide carboxylique et medicaments dont ils sont le principe actif
DE19845405C2 (de) 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
DE19916108C1 (de) * 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
US6908926B1 (en) * 1999-04-16 2005-06-21 Novo Nordisk A/S Substituted imidazoles, their preparation and use
WO2000063208A1 (en) 1999-04-16 2000-10-26 Novo Nordisk A/S Substituted imidazoles, their preparation and use
RU2278860C2 (ru) * 1999-04-28 2006-06-27 Санофи-Авентис Дойчланд Гмбх Производные триарил-содержащих кислот в качестве лигандов рецепторов ппар
SK15532001A3 (sk) 1999-04-28 2002-06-04 Aventis Pharma Deutschland Gmbh Deriváty kyselín s dvoma arylovými zvyškami ako ligandy receptorov PPAR a farmaceutické kompozície, ktoré ich obsahujú
US6284766B1 (en) 1999-04-30 2001-09-04 Neurogen Corporation 9H-pyrimido [4,5-b] indole derivatives: CRF1 specific ligands
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
CA2376919C (en) 1999-06-18 2008-11-04 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
JP2003504082A (ja) 1999-07-09 2003-02-04 コヘージョン テクノロジーズ, インコーポレイテッド エカリンポリペプチド、エカリンをコードするポリヌクレオチド、及びその利用のための方法
DE60004066T2 (de) 1999-07-29 2004-04-15 Eli Lilly And Co., Indianapolis Benzofurylpiperazine: 5-ht2c serotoninrezeptor agonisten
JP4792186B2 (ja) * 1999-09-01 2011-10-12 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング スルホニルカルボキサミド誘導体、その調製方法および医薬としてのその使用
TW200528436A (en) 1999-09-22 2005-09-01 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
SE9904413D0 (sv) 1999-12-03 1999-12-03 Astra Ab Comminuted form
CZ20021902A3 (cs) 1999-12-03 2002-11-13 Astrazeneca Ab Krystalická forma kyseliny (S)-2-ethoxy-3-[4-(2-{4-methansulfonyloxyfenyl}ethoxy)fenyl]propanové
PT1283735E (pt) 2000-03-31 2009-03-19 Prosidion Ltd Processo para melhoramento da sinalização de ilhéus na diabetes mellitus e para a sua prevenção
YU80302A (sh) 2000-04-25 2005-11-28 Kyorin Pharmaceutical Co. Ltd. Novi stabilni kristal derivata tiazolidinediona i postupak za proizvodnju istog
DE60129806T2 (de) 2000-04-28 2007-12-06 Asahi Kasei Pharma Corp. Neue bizyklische verbindungen
DE60115227T2 (de) 2000-05-11 2006-08-24 Bristol-Myers Squibb Co. Tetrahydroisochinolin-analoga als wachstumshormon-sekretagoga
EP1289526A4 (en) 2000-05-30 2005-03-16 Merck & Co Inc MELANOCORTIN RECEPTOR AGONISTS
PL359178A1 (en) * 2000-06-09 2004-08-23 Aventis Pharma Deutschland Gmbh Acylphenyl urea derivatives, methods for the production thereof and use thereof as a medicament
DE10038709A1 (de) 2000-08-09 2002-02-28 Aventis Pharma Gmbh Substituierte und unsubstituierte Benzooxathiazole sowie daraus abgeleitete Verbindungen
EP1182251A1 (en) * 2000-08-11 2002-02-27 Yissum Research Development Company of the Hebrew University of Jerusalem Methods for identifying compounds that inhibit ubiquitin-mediated proteolysis of IkB
ES2286137T3 (es) * 2000-08-23 2007-12-01 Eli Lilly And Company Derivados de acido oxazolil-arilpropionico y su uso como agonistas de ppar.
WO2002018355A1 (en) 2000-08-23 2002-03-07 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
WO2002046146A1 (fr) 2000-12-05 2002-06-13 Kyorin Pharmaceutical Co., Ltd. Derives d'acide carboxylique substitues
GB0031103D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
DE50111751D1 (de) 2000-12-21 2007-02-08 Sanofi Aventis Deutschland Neue diphenzylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung zur behandlung von lipidstoffwechselstörungen
HUP0303636A3 (en) * 2000-12-25 2006-02-28 Ono Pharmaceutical Co Dihydronaphthalenederivative compounds and pharmaceutical compositions containing them as active ingredient
MXPA03007284A (es) * 2001-02-15 2003-12-04 Pfizer Prod Inc Agonistas de receptor activador del proliferador de peroxisomas.
PE20021091A1 (es) 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
CA2448552A1 (en) * 2001-06-07 2002-12-19 Eli Lilly And Company Modulators of peroxisome proliferator activated receptors (ppar)
DE10154689A1 (de) 2001-11-09 2003-05-22 Probiodrug Ag Substituierte Aminoketonverbindungen
WO2003004458A1 (en) 2001-07-03 2003-01-16 Biovitrum Ab New compounds
FR2827859B1 (fr) 2001-07-30 2005-09-23 Lipha Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete
AU2002333456B2 (en) 2001-08-31 2008-07-17 Sanofi-Aventis Deutschland Gmbh Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as PPAR activators
ATE433440T1 (de) 2002-02-05 2009-06-15 Lilly Co Eli Harnstoff-linker verbindungen und ihre verwendung als ppar regulatoren
IL164249A0 (en) 2002-04-11 2005-12-18 Aventis Pharma Gmbh Acyl-3-carboxphenylurea derivatives, processes forpreparing them and their use
DE10215908B4 (de) 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
DE10225635C1 (de) 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
WO2004004665A2 (en) 2002-07-09 2004-01-15 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
US7148246B2 (en) * 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals

Also Published As

Publication number Publication date
AU2004215672A1 (en) 2004-09-10
CN100398526C (zh) 2008-07-02
NO20054396L (no) 2005-11-11
ZA200505768B (en) 2005-11-23
MA27742A1 (fr) 2006-02-01
RS20050594A (en) 2007-12-31
UY28210A1 (es) 2004-09-30
US20080167354A1 (en) 2008-07-10
CO5690578A2 (es) 2006-10-31
CL2004000392A1 (es) 2005-04-22
US7335671B2 (en) 2008-02-26
RU2005130002A (ru) 2006-01-27
MA27737A1 (fr) 2006-02-01
ATE365159T1 (de) 2007-07-15
US20050215596A1 (en) 2005-09-29
AR043432A1 (es) 2005-07-27
BRPI0407758A (pt) 2006-02-14
KR20050106461A (ko) 2005-11-09
ECSP055986A (es) 2006-01-16
SA04250153A (ar) 2005-12-03
DK1599453T3 (da) 2009-08-24
PT1599455E (pt) 2009-09-29
KR20050106462A (ko) 2005-11-09
CA2517386A1 (en) 2004-09-10
WO2004076426A1 (de) 2004-09-10
DK1599455T3 (da) 2009-11-09
AR043427A1 (es) 2005-07-27
KR20050105492A (ko) 2005-11-04
EP1599455B1 (de) 2009-07-01
TNSN05206A1 (en) 2007-06-11
WO2004076427A1 (de) 2004-09-10
JP2006519199A (ja) 2006-08-24
US20040209920A1 (en) 2004-10-21
CN100439347C (zh) 2008-12-03
AU2004215672B2 (en) 2010-01-07
AU2004215673A1 (en) 2004-09-10
JP2006519193A (ja) 2006-08-24
CN100439345C (zh) 2008-12-03
CN1753881A (zh) 2006-03-29
AU2004215673B2 (en) 2009-10-01
EP1599455A1 (de) 2005-11-30
PL378130A1 (pl) 2006-03-06
TNSN05204A1 (en) 2007-06-11
NO20054408D0 (no) 2005-09-22
IL170314A (en) 2010-11-30
MXPA05008995A (es) 2005-10-18
UY28209A1 (es) 2004-09-30
ATE430738T1 (de) 2009-05-15
NO20054408L (no) 2005-11-23
PA8596801A1 (es) 2004-09-16
CN1756748A (zh) 2006-04-05
US20080015238A1 (en) 2008-01-17
PE20040959A1 (es) 2005-01-17
ECSP055985A (es) 2006-01-16
DE502004009453D1 (de) 2009-06-18
US7259177B2 (en) 2007-08-21
MXPA05008988A (es) 2005-10-18
US7365084B2 (en) 2008-04-29
RU2005129992A (ru) 2006-02-10
EP1599453B1 (de) 2009-05-06
ZA200505765B (en) 2006-05-31
NO20054396D0 (no) 2005-09-22
BRPI0407907A (pt) 2006-02-14
MA27736A1 (fr) 2006-02-01
CA2516620A1 (en) 2004-09-10
EP1599453A1 (de) 2005-11-30
US7872034B2 (en) 2011-01-18
ES2287700T3 (es) 2007-12-16
BRPI0407814A (pt) 2006-02-14
PL378437A1 (pl) 2006-04-03
US20050101637A1 (en) 2005-05-12
EP1599452B1 (de) 2007-06-20
TW200510352A (en) 2005-03-16
JP2006519194A (ja) 2006-08-24
HRP20050742A2 (en) 2006-09-30
ES2326418T3 (es) 2009-10-09
CO5690580A2 (es) 2006-10-31
DK1599452T3 (da) 2007-10-01
NO20054398L (no) 2005-11-02
WO2004076428A1 (de) 2004-09-10
CA2517381A1 (en) 2004-09-10
PT1599452E (pt) 2007-09-12
DE10308355A1 (de) 2004-12-23
ATE435217T1 (de) 2009-07-15
ES2329366T3 (es) 2009-11-25
DE502004009690D1 (de) 2009-08-13
PE20050293A1 (es) 2005-05-24
AU2004215677B2 (en) 2010-01-07
AR043433A1 (es) 2005-07-27
TW200500349A (en) 2005-01-01
MXPA05008951A (es) 2005-11-04
PE20050292A1 (es) 2005-05-24
HRP20050743A2 (en) 2006-08-31
IL170316A (en) 2010-11-30
NO20054398D0 (no) 2005-09-22
OA13035A (en) 2006-11-10
EP1599452A1 (de) 2005-11-30
HRP20050744A2 (en) 2006-09-30
OA13034A (en) 2006-11-10
CL2004000391A1 (es) 2005-01-07
DE502004004139D1 (de) 2007-08-02
AU2004215677A1 (en) 2004-09-10
RU2005129995A (ru) 2006-01-27
TW200508210A (en) 2005-03-01
PT1599453E (pt) 2009-07-14
CN1753879A (zh) 2006-03-29

Similar Documents

Publication Publication Date Title
PT1599455E (pt) Derivados do ácido 4-(3-(2-fenil-oxazol-4-ilmetoxi)-ciclohexiloxi)- butanóico e compostos relacionados como moduladores de ppar para o tratamento de diabetes de tipo 2 e aterosclerose
LT2937341T (lt) 4-(benzil)-piperazin-1-karboksilinės rūgšties fenilamido dariniai ir giminingi junginiai kaip riebalų rūgščių amido hidrolazės (rrah) moduliatoriai, skirti nerimo, skausmo ir kitų būklių gydymui
NO20062030L (no) Derivater av N-heterocyklylmetylbenzamider, fremgangsmate for fremstilling derav og anvendelse av forbindelsene t terapeutiske midler.
IL173591A0 (en) 2-(quinoxalin-5-ylsulfonylamino)-benzamide compounds as cck2 modulators
PL1848700T3 (pl) Sole kwasu (s)-2-amino-3-{4-[4-(2,4-diokso-tiazolidyn-5-ylometylo)- fenoksy]-fenylo}-propionowego i jego estrów metylowych jako inhibitory interleukiny do leczenia otyłości lub cukrzycy
EP1756040A4 (en) PHENYL CARBOXAMIDE COMPOUNDS FOR USE AS BETA SECRETASE INHIBITORS IN THE TREATMENT OF ALZHEIMER'S DISEASE
WO2006067103A3 (en) Process for the preparation of a 2-pyridylethylcarboxamide derivative
PL1651604T3 (pl) Związki N-´2-(2-pirydynylo)etylobenzamidy i ich zastosowanie jako środki grzybobójcze
WO2005105739A3 (en) Cyanopyrrole containing cyclic carbamate and thiocarbamate biaryls and methods for preparing the same
AU2003235814A1 (en) Novel process for the preparation of trans-3- ethyl-2,5- dihydro-4- methyl-n-(2-( 4-(((((4-methyl cyclohexyl) amino)carbonyl) amino)sulfonyl) phenyl)ethyl) -2-oxo-1h-pyrrole -1-carboxamide
AU2003280143A1 (en) N-(4-(piperazin-1-yl)-phenyl-2-oxazolidinone-5-carboxamide derivates and related compounds as antibacterial agents
PL337397A1 (en) Novel derivatives of 4-{3-[4-(imidazol-1-yl)phenylsuphanyl]phenyl}tetrahydropyrane-4-carboxamide and method of obtaining them as well as novel intermediate compounds
AU2003292449A1 (en) Process for the preparation of 3-(2-(3,4-dimethoxybenzoyl)-4,5- dimethoxyphenyl) -pentan-2-one
ZA200601986B (en) Process for the synthesis of 3-(3-fluoro-4-hydroxyphenyl)-7-hydroxynaphthonitrile

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)